Clinical Trial Update: The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study investigating high-dose aldesleukin (interleukin-2) for metastatic renal cell carcinoma has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-19